NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Key Who May Qualify: - Participant has a primary diagnosis of schizophrenia - Participant is experiencing an acute exacerbation or relapse of symptoms and currently warrants hospitalization. - Participants taking prohibited medications, including antipsychotics, must discontinue before study participation - Participant is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements Key Who Should NOT Join This Trial: - Participant has known hypersensitivity to any component of the formulation of NBI-1117568. - Participant has an unstable or poorly controlled medical condition or chronic disease - Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others - Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening - Participant has a positive alcohol test or drug screen for disallowed substances - Participants have a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements. Note: Other protocol-specified inclusion/exclusion criteria may apply. Always talk to your doctor about whether this trial is right for you.